Effects of Melatonin on Cognitive Dysfunction After Electroconvulsive Therapy (ECT)

Comparing the Effects of Melatonin and Placebo on Cognitive Side Effects of Electroconvulsive Therapy (ECT) in Patients with Mood Disorders: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015103124793N1

Enrollment

Registered

2016-12-20

Start date

2015-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mood Disorders. Mood [affective] disorders

Interventions

Intervention 1: Melatonine, 3 mg tablet, orally, once a day, for a period of 4 weeks. Intervention 2: Placebo tablet, orally, once a day, for a period of 4 weeks.

Treatment - Drugs

Placebo

Melatonine, 3 mg tablet, orally, once a day, for a period of 4 weeks

Placebo tablet, orally, once a day, for a period of 4 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: affective disorders lead to hospitalization in psychiatric wards; age 18 to 65 years; having informed consent. Exclusion criteria: substance abuse; schizophrenia; previous treatment with electroconvulsive therapy; having psychosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Patients' mental status. Timepoint: pretreatment, after finishing ECT sessions, 4 weeks after finishing all sessions. Method of measurement: Mini-mental Status Examination Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaleb Badri

Baqiyatallah University of Medical Sciences

dr_badri52@yahoo.com+98 21 8126 3891

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026